The TrumpRx website claims to offer the best prices for medications. Here’s where Americans still pay more — and much more.

Johnson & Johnson's much-anticipated oral IL-23 inhibitor, icotrokinra, has claimed FDA approval as a first-line treatment ...

For anxiety and depression that co-occur with diabetes and obesity, semaglutide and, to a lesser extent, liraglutide might be ...

This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." ...

With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.

As drug policy moves toward public health strategies, Mexico shows how criminal control over drug markets can become a ...

Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to ...

Stoke Therapeutics is developing a drug designed to reduce seizures and restore some of their lost developmental function.

The patent on Semaglutide, an active ingredient in most weight-loss drugs is set to expire on March 20, making generic anti-obesity medicines much cheaper. It carries the potential to transform how ...

The head of an Ottawa health centre that's home to one of Ontario's addiction recovery hubs is stressing the need for a ...

Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers complete skin clearance and favorable safety profile in a once-daily pill ICOTYDE ...